Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease

Heart and Vessels

Volumn 25, Issue 3, 2010, Pages 203-208

  Omae, Kiyotsugu ^a,b   Ogawa, Tetsuya ^b   Nitta, Kosaku ^b  

^a Yoshikawa Hospital   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensinconverting enzyme inhibitor; Chronic kidney disease; Glomerular filtration rate; Hypertension; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROSCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956155373     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-009-1188-4     Document Type: Article

References (42)

1. Liu H, Yu J, Chen F, Li J, Hu D (2007) Inpatients with coronary heart disease have a high prevalence of chronic kidney disease based on estimated glomerular filtration rate (eGFR) in China. Heart Vessels 22:223-228
2. Norris K, Vaughn C (2003) The role of renin-angiotensinaldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther 1:51-63
3. Vogt L, Kocks MJ, Navis G (2004) Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and nondiabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Minerva Med 95:395-409
4. Ruggenenti P (2004) Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 24:158-167
5. Noda M, Fukuda R, Matsuo T (1997) Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int 63(suppl):S136-S139
6. Ots M, Mackenzie HS, Brenner BM (1998) Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9:224-230
7. Ishimitsu T, Kameda T, Akashiba A (2007) Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 30:621-626
8. Fujita T, Ando K, Nishimura H, Ideura T, Tasuda G, Isshiki M, Takahashi K; Cilnidipine versus Amlodipine Randomised Trial for Renal Disease (CARTER) Study Invesigators (2007) Antiproteinuric effect of calcium channel blocker cilnidipine added to renninangiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 72:1543-1549
9. Gryglewski RJ, Uracz W, Marcinkiewicz E (2002) Bradykinin as a major endogenous regulator of endothelial function. Pediatr Pathol Mol Med 21:279-290
10. Padia SH, Howell NL, Carey RM (2006) Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 47:537-544
11. Miura S, Kiya Y, Saku K (2008) Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 22:139-146
12. Ginsberg JM, Chang BS, Matarese RA, Garella S (1983) Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309:1543-1546
13. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 50:927-937 (Pubitemid 350130278)
14. Segura J, Garcia-Donaire JA, Ruilope LM (2005) Calcium channel blockers and renal protection: insights from the latest clinical trials. J Am Soc Nephrol 16(suppl 1):S64-S66
15. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostang SG; African American Study of Kidney Disease and Hypertension Study Group (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421-2431
16. Campbell R, Remuzzi G, Ruggenenti P (2003) Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63:1094-1103
17. Ferrari P, Marti HP, Pfister M, Frey FJ (2002) Additive antiproteinuric effect of combined ACE inhibitor and angiotensin II receptor blockade. J Hypertens 20:125-130
18. Weir MR, Henrich WL (2000) Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 9:403-411
19. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952-1961
20. Ichikawa I (1996) Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 50:684-692
21. Hutchison FN, Cui X, Webster SK (1995) The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 6:1216-1222
22. Shoda J, Kanno Y, Suzuki H (2006) A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with nondiabetic nephropathy. Intern Med 45:193-198
23. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131-140
24. Schanstra JP, Bachvarova M, Neau E (2007) Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. Kidney Int 72:442-454
25. MacLaughlin M, Monserrat AJ, Muller A (1998) Role of kinins in the renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure. Kidney Blood Press Res 21:329-334
26. Tschöpe C, Seidl U, Reinecke A (2003) Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. Int Immunopharmacol 3:335-344
27. Allard J, Buléon M, Cellier E (2007) ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 293:F1083-F1092
28. Okada H, Watanabe Y, Suzuki H (2004) Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensinconverting enzyme blockade. J Am Soc Nephrol 15:2404-2413
29. Kimura H (2005) Increased expression of plasminogen activator inhibitor-1 in hypoxic renal injury and its pathological significance in progression of advanced renal disease (in Japanese). Rinsho Byori 53:749-758
30. Eddy AA, Fogo AB (2006) Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17:2999-3012
31. Skurk T, Lee YM, Hauner H (2001) Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 37:1336-1340
32. Gesualdo L, Ranieri E, Monno R (1999) Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 56:461-470
33. Yoshida M, Naito Y, Takada Y (2002) L-158,809 and (D-Ala(7))-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells. Thromb Res 105:531-536
34. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK (1995) Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant 10:1353-1360
35. Morita S, Fukuhara S, Akizawa T, Asano Y, Koshikawa S, Koide K, Kurokawa K (2006) Prognostic factors for a composite endpoint of renal outcomes in patients with chronic kidney disease. Ther Apher Dial 10:72-77
36. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP (1997) Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 8:199-207
37. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G (1998) Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53:1209-1216
38. Donadio JV, Bergstralh EJ, Grande JP, Rademcher DM (2002) Proteinuria patterns and their association with subsequent endstage renal disease in IgA nephropathy. Nephrol Dial Transplant 17:1197-1203
39. Vikse BE, Aasarod K, Bostad L, Iversen BM (2003) Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transplant 18:517-523
40. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, Levey AS; ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group (2005) The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 67:265-271
41. Hsu SI, Couser WG (2003) Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 14 (suppl 2):S186-S191
42. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884